Company
Headquarters: Santa Clara, CA, United States
Employees: 352
CEO: Ms. Laura A. Francis
$858.7 Million
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Abbott | $216.15 B |
| Boston Scientific Corporation | $140.40 B |
| Stryker | $133.15 B |
| Medtronic | $123.20 B |
| Edwards Lifesciences Corporation | $50.10 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $138.9 M |
| EBITDA | $-41,503,000 |
| Gross Profit TTM | $109.4 M |
| Profit Margin | -31.20% |
| Operating Margin | -32.18% |
| Quarterly Revenue Growth | 21.60% |
SI-BONE, Inc. has the following listings and related stock indices.
Stock: NASDAQ: SIBN
Stock: FSX: 2K3
Stock: Munich: 2K3